Sterility Requirements for Ophthalmic Hyaluronic Acid: A Supplier-Side Technical Guide

Meta Title: Sterility Requirements for Ophthalmic Hyaluronic Acid

Meta Description: Sterility in ophthalmic hyaluronic acid means three tests — bioburden, SAL, and endotoxin. Learn why HA needs aseptic processing and how to audit it properly.

Keywords: sterility requirements ophthalmic hyaluronic acid, sterile sodium hyaluronate eye drops, SAL 10^-6 ophthalmic, aseptic processing HA, gamma irradiation hyaluronic acid molecular weight, bioburden USP 61 62, USP 71 sterility test, EP 2.6.1

Ask three buyers of ophthalmic-grade hyaluronic acid whether their supplier's product is "sterile" and you will likely get three different answers. One points to a COA that says "sterility: passed." The second points to a bioburden test that came back below a certain colony count. The third points to an endotoxin result of "<0.05 EU/mg."

All three are real tests. None of them is interchangeable with the other two. And confusing them is, in our experience, the single most common mistake buyers make when they evaluate a sodium hyaluronate supplier for ophthalmic use.

This article unpacks what "sterility" actually means for ophthalmic hyaluronic acid across the regulatory, manufacturing and supplier sides of the equation — and explains why HA is one of the few pharmaceutical excipients where achieving sterility is a genuine engineering problem, not just a release-spec line item.

1. The Three-Layer Confusion: Sterility, Bioburden, and Endotoxin Are Not the Same Thing

Ophthalmic HA products are subject to three distinct microbial-safety layers, each measuring something different:

The layers are hierarchical. A material can have bioburden well below the acceptance limit and still not meet sterility. A material can meet sterility on a spot test yet carry residual endotoxin above the ophthalmic limit — because endotoxin is a molecule, not a living organism, and it survives sterilization of the bacteria that produced it.

We covered endotoxin in depth in our previous guide on endotoxin control in ophthalmic HA. This article focuses on the other two layers — sterility assurance and microbial limits — and on what they mean for the raw material supply chain.

2. Why Ophthalmic Products Live at the Top of the Sterility Pyramid

The eye is one of the most unforgiving routes of administration in pharmaceutical manufacturing. Unlike oral or intravenous routes, it has limited immune clearance capacity. The cornea and anterior chamber lack a vascular lymphoid system, so once a viable microorganism establishes on the ocular surface or inside the anterior chamber, local defences are largely cell-autonomous.

The clinical consequences are not theoretical:

· Endophthalmitis after intraocular surgery, when caused by Gram-negative organisms, has historically carried visual outcomes worse than 20/200 in a meaningful fraction of cases, even with prompt treatment.

· Microbial keratitis associated with contaminated contact lens solutions or eye drops remains a leading cause of preventable corneal blindness globally.

· Toxic Anterior Segment Syndrome (TASS) — which, as the prior article notes, is driven by endotoxin, not viable organisms — still appears regularly in ophthalmic surgery safety alerts, underscoring that both viable microbes and non-viable pyrogens must be controlled.

Regulators respond by classifying all ophthalmic preparations (eye drops, ointments, intraocular viscoelastics, intraocular rinses, IOL coatings, contact lens solutions intended for sterile use) as products that must be sterile at the point of administration, and — for multi-dose formats — must additionally resist post-opening contamination, typically through preservative systems.

3. Sterility Requirements Across Ophthalmic HA Applications

The required sterility assurance level (SAL) is not a flat number across all ophthalmic HA products. It scales with the invasiveness of the application and the number of doses:

Two things are worth noticing from this table.

First, for every ophthalmic HA product that reaches the eye directly (not through a preserved multi-dose container), the SAL target is 10⁻⁶ — the same standard applied to intravenous drugs and implantable medical devices. The eye is treated by regulators as if it were a sterile compartment.

Second, endotoxin limits are layered on top of the sterility standard, not a replacement. A product can pass sterility and still fail endotoxin. Both must be demonstrated.

4. The HA Sterilization Problem: Most Standard Methods Damage the Molecule

This is where hyaluronic acid becomes genuinely unusual as a pharmaceutical excipient. For most small-molecule APIs and many biologics, terminal sterilization of the finished, packaged product is the preferred approach — it offers the highest sterility assurance, is auditable by physical dose, and minimizes recontamination risk after sterilization.

For sodium hyaluronate destined for ophthalmic use, almost every terminal sterilization method is problematic.

4.1 Gamma Irradiation (ISO 11137)

γ-radiation is the gold standard terminal sterilization method for many medical devices and pharmaceutical powders. For HA, however, it is a molecular-weight scalpel.

Published data on γ-irradiated HA consistently show a dose-dependent, irreversible reduction in molecular weight through oxidative chain scission:

· ~20 kGy: HA molecular weight drops to roughly 230 kDa from a starting point in the high-MW range (PMC6680453).

· ~40 kGy: drops further to ~140 kDa.

· ~60 kGy: drops to ~60 kDa — a catastrophic loss for an OVD whose rheology depends on the 1.5–2.5 MDa range.

· Even at the low doses used for many ophthalmic powders, viscosity, pH, and colour are measurably altered, and new UV absorption peaks appear around 265 nm indicating unsaturated bond formation (Pubmed 26049989, Food Chem 2008).

Since ophthalmic HA is selected specifically for its molecular-weight-dependent rheology — viscoelasticity in OVDs, retention time in eye drops — γ-sterilization of the finished HA product is, for most ophthalmic grades, not an option.

4.2 Ethylene Oxide (ISO 11135)

EO sterilization avoids chain scission but introduces residual ethylene oxide and ethylene chlorohydrin — toxic residues that must be extensively degassed and validated. EO also causes measurable degradation in HA and, more importantly, leaves a residue profile that must meet tight limits for ophthalmic contact. Recent whitepapers (Sterigenics, ophthalmic APIs) demonstrate EO feasibility for several ophthalmic APIs, but HA is not among them.

4.3 Moist Heat (Autoclave, ISO 17665)

Typical autoclave cycles (121 °C for 15 minutes) cause hydrolytic chain scission in HA. Viscosity drops significantly, and the molecular weight distribution broadens. Ophthalmic applications are precisely the ones where the original MW profile matters most.

4.4 Dry Heat

Classical dry-heat depyrogenation requires 250 °C for ≥30 minutes. HA polymer decomposes well below that temperature.

4.5 Sterile Filtration (0.22 µm)

This is the one method that does not damage HA — but it is constrained by viscosity. High-MW HA solutions (≥1.5 %) above a certain viscosity are extremely difficult to push through a sterilizing-grade filter at acceptable throughput. This is precisely why formulation chemists have to balance molecular weight and concentration with filterability when designing ophthalmic HA products (as noted in Runxin's ophthalmic-grade overview).

The practical conclusion: for most ophthalmic HA, sterility is achieved through aseptic processing, not through terminal sterilization of the final product.

5. Why Aseptic Processing Is the Default — And What That Costs

Aseptic processing means the product, the primary packaging, and the filling environment are all independently sterilized before they come together inside a controlled environment.

For ophthalmic HA, this typically looks like:

· Bulk HA powder sterilized by filtration from a sterile solution, or by other means proven not to damage MW (often, bioburden is simply controlled so low that the subsequent compounding and filtration achieves the necessary assurance).

· Primary packaging (vials, bottles, dropper tips, syringes) sterilized by autoclave, dry heat, or γ-irradiation of the empty components — all of which are feasible because HA is not present yet.

· Filling and sealing performed in an ISO 5 / Grade A environment within an ISO 7 / Grade B background, per EU GMP Annex 1 (2022 revision, fully in force August 2023).

· Sterilizing filtration of the final solution through a 0.22 µm (or smaller) filter immediately before fill.

· Container-closure integrity verified for every batch (e.g., vacuum decay, high-voltage leak detection).

This is materially more expensive and more demanding than terminal sterilization. It requires:

· Validated cleanrooms with continuous environmental monitoring (viable and non-viable particulates).

· Aseptic process simulation (media fills) run at defined frequencies, using TSB or similar growth media, processed through the entire filling line to validate the aseptic chain.

· Qualified operators trained, gowned, and monitored in aseptic discipline.

· Rigorous qualification of all utilities — purified water, WFI, clean steam, compressed gases.

Annex 1's 2022 revision placed new emphasis on Contamination Control Strategies (CCS) — a facility-wide, documented program for managing microbial and particulate contamination across the sterile manufacturing lifecycle. A supplier who cannot walk you through their CCS, their media-fill results, and their environmental monitoring trending is not operating at the standard ophthalmic HA requires.

6. Raw-Material Bioburden: The Test Most Buyers Never Ask About

Here is a subtle but consequential point: sterility testing (USP <71>) is normally performed on the finished product, not on the raw material. Raw materials like bulk HA powder are typically tested for bioburden (microbial enumeration) and specified microorganisms, not for full sterility.

The relevant compendial tests are:

· USP <61> / EP 2.6.12 — Microbial Enumeration Tests (TAMC for total aerobic microbial count, TYMC for total yeasts and moulds count).

· USP <62> / EP 2.6.13 — Tests for Specified Microorganisms (e.g., absence of Escherichia coli, Salmonella spp., Staphylococcus aureus, Pseudomonas aeruginosa, bile-tolerant Gram-negative bacteria, depending on route and dose).

For ophthalmic-grade HA, typical acceptance criteria are tight:

· TAMC: ≤10² CFU/g (some manufacturers set ≤10 CFU/g for ophthalmic grade).

· TYMC: ≤10¹ CFU/g.

· Objectionable organisms: absent in 1 g (or 10 g, depending on the pharmacopoeial category assigned to the product).

Why this matters for the finished-product manufacturer: raw material bioburden sets the starting microbial load that the aseptic process must reduce to SAL 10⁻⁶. The higher the starting bioburden, the more demanding the sterilizing filtration step, the shorter the filter life, and the greater the risk of incomplete kill.

In practice, this means:

· A finished-product manufacturer cannot accept an HA raw material with poor bioburden and rely on the aseptic process to compensate.

· Buyers should request bioburden data for each lot, not just a "sterility: passed" certificate — the powder is not sterile at the time it is received.

· A credible supplier controls bioburden through upstream fermentation hygiene, clean-room handling, and packaging, and provides lot-level data.

7. Regulatory Framework in 2026

The regulatory picture relevant to sterility of ophthalmic HA in 2026 rests on several harmonized pillars:

· USP <71> Sterility Tests — harmonized with EP 2.6.1 and JP 4.06; governs how finished-product sterility is verified. As of recent compendial updates, growth promotion and suitability testing requirements remain strictly enforced.

· USP <61> / <62> — microbial enumeration and specified organisms for raw materials.

· EU GMP Annex 1 (2022 revision) — fully in force since August 2023; the most detailed globally applicable standard for sterile manufacturing, including the mandatory CCS.

· FDA Guidance: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice — US counterpart to Annex 1.

· ISO 11137 (γ), ISO 11135 (EO), ISO 17665 (moist heat) — terminal sterilization methods; for HA, mainly relevant to primary packaging sterilization, not to the product itself.

· NMPA — China's regulator accepts both USP and EP test methods for HA APIs destined for ophthalmic use and has aligned its expectations around Annex 1 principles for sterile facilities.

A supplier seeking to serve global ophthalmic customers should therefore be able to demonstrate compliance across at least three pharmacopoeias (USP/EP/JP/NMPA) and maintain an Annex 1-grade sterile manufacturing environment for the ophthalmic-grade lines.

8. Seven Audit Questions That Separate a Sterile-Capable HA Supplier From a Sterile-Marketed One

Drawing the threads together, here are the questions that distinguish a supplier with genuine aseptic capability from one whose COA says "sterile" but whose facility is not set up to support the claim for ophthalmic use.

Is the ophthalmic-grade HA manufactured in an ISO 5 / Grade A environment within a Grade B background, per Annex 1? If filling is done at Grade C or worse, the claim of ophthalmic-grade sterility should be questioned.

How is the bulk powder brought to low bioburden, and what are the lot-level TAMC/TYMC results? A supplier who only reports end-product sterility and not raw-material bioburden is hiding half the picture.

What sterilization method is applied to the primary packaging? Since HA itself is almost always aseptically filled rather than terminally sterilized, packaging sterilization is the only terminal sterilization step in the chain.

What is the sterilizing filtration specification for the final ophthalmic solution, and how is filter integrity verified? Look for documented bubble-point or diffusive-flow testing.

How frequently are media fills performed, and what were the most recent results? Annex 1 recommends media fills at least twice per year per aseptic line; recent trends matter more than historical perfection.

What does the Contamination Control Strategy look like, and how is it maintained across utilities, personnel, and premises? CCS has been mandatory under Annex 1 since 2023.

Can the supplier provide method validation for the compendial sterility test on their specific product matrix (USP <71> suitability), including bacteriostasis/fungistasis demonstration? HA viscosity can interfere with sterility testing just as it does with endotoxin testing (see our prior endotoxin article); the method must be shown to work for the specific product, not for a generic broth.

What a mature program looks like at Runxin

At Shandong Runxin Biotechnology, we have manufactured pharmaceutical-grade sodium hyaluronate since 1998. Our ophthalmic-grade lines operate under ISO 13485 and cGMP frameworks, with a registered DMF 036368 on file with the U.S. FDA and supply to ophthalmic customers across 34 export markets. Our sterile manufacturing environment, validated media-fill programs, compendial-method validation for USP <71> / EP 2.6.1 on our specific matrices, and lot-level bioburden reporting are available for audit discussion.

We don't expect buyers to take a "sterile" claim on trust. We expect them to ask the seven questions above, and we are prepared to answer all of them — with documentation, not with marketing.

If you are specifying or re-qualifying sodium hyaluronate for an ophthalmic application and want a technical conversation about sterility, bioburden, and endotoxin control at the raw-material level, get in touch with Runxin's ophthalmic raw materials team.

About the author. This article was prepared by the technical team at Shandong Runxin Biotechnology Co., Ltd., a pharmaceutical-grade sodium hyaluronate manufacturer established in 1998. Runxin holds U.S. FDA DMF 036368, ISO 13485 certification, COSMOS, HALAL, and cGMP alignment, and supplies HA to ophthalmic, orthopedic, and aesthetic markets across 34 countries.

Sources & further reading

· USP <71> Sterility Tests; USP <61> Microbial Enumeration Tests; USP <62> Tests for Specified Microorganisms

· European Pharmacopoeia 2.6.1 Sterility, 2.6.12 Microbial Enumeration, 2.6.13 Specified Microorganisms, 2.6.14 Bacterial Endotoxins

· Japanese Pharmacopoeia 4.06 Sterility Test

· EU GMP Annex 1: Manufacture of Sterile Medicinal Products (2022 revision, in force Aug 2023) — EMA link

· FDA Guidance: Sterile Drug Products Produced by Aseptic Processing — Current GMP

· ISO 11137 (γ), ISO 11135 (EO), ISO 17665 (moist heat), ISO 15798 (OVDs)

· Sterigenics whitepaper: The Effect of Gamma and Ethylene Oxide Sterilization on a Selection of Active Pharmaceutical Products for Ophthalmics — link

· PMC6680453, Gamma-Irradiation-Prepared Low Molecular Weight Hyaluronic Acid Promotes Skin Wound Healing — link

· Pubmed 26049989, Structural and antioxidant properties of gamma irradiated hyaluronic acid (Food Chem, 2008) — link

· PMC10236422, Local production of eye drops in the hospital or pharmacy setting — link

· HiMedia Labs, USP <71> Compliance Overview (Jan 2026) — link

· Related Runxin articles: Endotoxin Control in Ophthalmic HA; Ophthalmic-Grade Sodium Hyaluronate — What Buyers Should Know